OPC Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
OPC Pharmaceutical has been growing earnings at an average annual rate of 3.2%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 0.8% per year. OPC Pharmaceutical's return on equity is 12.1%, and it has net margins of 9.1%.
Key information
3.2%
Earnings growth rate
3.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | 0.8% |
| Return on equity | 12.1% |
| Net Margin | 9.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How OPC Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 951,225 | 86,159 | 324,893 | 0 |
| 30 Jun 24 | 979,668 | 95,290 | 334,304 | 0 |
| 31 Mar 24 | 1,027,903 | 103,420 | 347,779 | 0 |
| 31 Dec 23 | 1,004,887 | 104,691 | 332,311 | 0 |
| 30 Sep 23 | 983,349 | 115,809 | 325,179 | 0 |
| 30 Jun 23 | 1,039,274 | 121,611 | 351,220 | 0 |
| 31 Mar 23 | 989,310 | 114,485 | 306,463 | 0 |
| 31 Dec 22 | 1,171,614 | 128,118 | 355,073 | 0 |
| 30 Sep 22 | 1,225,353 | 129,058 | 324,616 | 0 |
| 30 Jun 22 | 1,245,135 | 126,068 | 309,918 | 0 |
| 31 Mar 22 | 1,225,233 | 115,178 | 344,855 | 0 |
| 31 Dec 21 | 1,123,728 | 112,961 | 313,516 | 0 |
| 30 Sep 21 | 1,062,751 | 105,759 | 304,777 | 0 |
| 30 Jun 21 | 978,151 | 94,020 | 283,233 | 0 |
| 31 Mar 21 | 977,763 | 98,960 | 264,080 | 0 |
| 31 Dec 20 | 965,591 | 94,798 | 257,049 | 0 |
| 30 Sep 20 | 906,638 | 85,631 | 245,698 | 0 |
| 30 Jun 20 | 961,404 | 92,235 | 262,937 | 0 |
| 31 Mar 20 | 1,011,614 | 95,729 | 292,433 | 0 |
| 31 Dec 19 | 989,390 | 90,392 | 305,675 | 0 |
| 30 Sep 19 | 1,021,060 | 95,010 | 321,185 | 0 |
| 30 Jun 19 | 977,318 | 88,435 | 315,255 | 0 |
| 31 Mar 19 | 963,910 | 87,648 | 316,573 | 0 |
| 31 Dec 18 | 1,002,478 | 88,013 | 334,063 | 0 |
| 30 Sep 18 | 964,915 | 82,013 | 325,227 | 0 |
| 30 Jun 18 | 968,353 | 84,157 | 329,435 | 0 |
| 31 Mar 18 | 946,446 | 80,677 | 318,277 | 0 |
| 31 Dec 17 | 944,850 | 78,262 | 333,701 | 0 |
| 30 Sep 17 | 928,090 | 80,059 | 325,453 | 0 |
| 30 Jun 17 | 901,043 | 75,868 | 319,801 | 0 |
| 31 Mar 17 | 870,910 | 72,526 | 321,564 | 0 |
| 31 Dec 16 | 790,405 | 70,251 | 284,970 | 0 |
| 30 Sep 16 | 718,866 | 65,252 | 274,681 | 0 |
| 30 Jun 16 | 684,761 | 61,213 | 265,497 | 0 |
| 31 Mar 16 | 672,670 | 62,380 | 260,881 | 0 |
| 31 Dec 15 | 663,213 | 63,238 | 252,817 | 0 |
| 30 Sep 15 | 658,244 | 68,056 | 254,006 | 0 |
| 30 Jun 15 | 634,702 | 62,077 | 252,052 | 0 |
| 31 Mar 15 | 630,434 | 53,260 | 233,759 | 0 |
| 31 Dec 14 | 612,475 | 58,909 | 219,570 | 0 |
| 30 Sep 14 | 632,802 | 50,617 | 216,408 | 0 |
| 30 Jun 14 | 623,465 | 53,294 | 217,386 | 0 |
| 31 Mar 14 | 604,173 | 64,489 | 219,164 | 0 |
| 31 Dec 13 | 563,819 | 56,254 | 202,055 | 0 |
Quality Earnings: OPC has high quality earnings.
Growing Profit Margin: OPC's current net profit margins (9.1%) are lower than last year (11.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OPC's earnings have grown by 3.2% per year over the past 5 years.
Accelerating Growth: OPC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: OPC had negative earnings growth (-25.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).
Return on Equity
High ROE: OPC's Return on Equity (12.1%) is considered low.